Welcome to our dedicated page for Healthequity SEC filings (Ticker: HQY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HealthEquity, Inc. filings document regulatory disclosures for an HSA custodian and consumer-directed benefits administrator. Recent 8-K reports cover operating results and financial condition, guidance furnished under Regulation FD, HSA account and asset metrics, revenue categories, stock repurchase activity, and hedging used to reduce HSA cash repricing risk.
Governance filings record board appointments and committee assignments, annual meeting vote results, auditor ratification, advisory executive compensation votes, executive employment agreement amendments, severance arrangements, equity award terms, and technology-organization leadership responsibility. These disclosures frame the company's capital allocation, compensation governance, risk oversight and public-company reporting obligations.
HealthEquity, Inc. (HQY) – Form 4 insider filing
Director Stuart B. Parker reported the grant of 2,003 restricted stock units (RSUs) on 06/26/2025. The units were awarded at $0 cost and will vest in full at the company’s next annual shareholder meeting. Settlement in common shares is scheduled for 02/01/2028, or earlier upon a change-of-control, termination of service, or death, as defined in the 2024 Equity Incentive Plan.
Following the grant, Parker’s direct beneficial ownership rises to 21,835 HQY shares. No open-market purchases, sales, or derivative security exercises were reported, and Table II shows no option activity.
This filing reflects routine director equity compensation. While the transaction modestly increases insider alignment, the 2,003-share grant is immaterial relative to HealthEquity’s total shares outstanding and is unlikely to influence the company’s valuation or liquidity.
HealthEquity (NASDAQ:HQY) filed an 8-K disclosing results of its 26 June 2025 annual meeting and a significant capital-return action.
Shareholder votes: All nine directors were re-elected; PricewaterhouseCoopers LLP was ratified as auditor (82,962,314 for, 346,165 against); and FY-25 executive compensation was approved on an advisory basis (76,093,619 for, 3,218,477 against).
Capital allocation: The board authorized a new $300 million share-repurchase program, supplementing the existing $300 million authorization from August 2024. Repurchases may occur through open-market or privately negotiated transactions, including Rule 10b5-1 plans, and can be suspended at any time.
No other material disclosures were made.